1. Home
  2. VRTX vs C Comparison

VRTX vs C Comparison

Compare VRTX & C Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • C
  • Stock Information
  • Founded
  • VRTX 1989
  • C 1812
  • Country
  • VRTX United States
  • C United States
  • Employees
  • VRTX N/A
  • C N/A
  • Industry
  • VRTX EDP Services
  • C Major Banks
  • Sector
  • VRTX Technology
  • C Finance
  • Exchange
  • VRTX Nasdaq
  • C Nasdaq
  • Market Cap
  • VRTX 115.6B
  • C 132.9B
  • IPO Year
  • VRTX 1991
  • C N/A
  • Fundamental
  • Price
  • VRTX $436.00
  • C $73.09
  • Analyst Decision
  • VRTX Buy
  • C Buy
  • Analyst Count
  • VRTX 26
  • C 14
  • Target Price
  • VRTX $512.54
  • C $86.32
  • AVG Volume (30 Days)
  • VRTX 2.1M
  • C 12.1M
  • Earning Date
  • VRTX 05-05-2025
  • C 07-11-2025
  • Dividend Yield
  • VRTX N/A
  • C 3.06%
  • EPS Growth
  • VRTX N/A
  • C 85.23
  • EPS
  • VRTX N/A
  • C 6.33
  • Revenue
  • VRTX $11,099,700,000.00
  • C $71,819,000,000.00
  • Revenue This Year
  • VRTX $10.36
  • C $19.70
  • Revenue Next Year
  • VRTX $10.61
  • C $3.01
  • P/E Ratio
  • VRTX N/A
  • C $11.55
  • Revenue Growth
  • VRTX 8.98
  • C 3.25
  • 52 Week Low
  • VRTX $377.85
  • C $53.51
  • 52 Week High
  • VRTX $519.88
  • C $84.74
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 39.81
  • C 55.41
  • Support Level
  • VRTX $416.60
  • C $74.79
  • Resistance Level
  • VRTX $448.00
  • C $76.32
  • Average True Range (ATR)
  • VRTX 13.25
  • C 1.25
  • MACD
  • VRTX -0.20
  • C -0.05
  • Stochastic Oscillator
  • VRTX 37.85
  • C 54.76

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About C Citigroup Inc.

Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.

Share on Social Networks: